Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.67 |
| ▸ | CNR1 | P21554 | 4/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585315 | 0.86 | CNR2 (0.58) | CNR2CNR1KCNH2 | |
| SCHEMBL4970695 | 0.86 | CNR2 (0.67) | CNR2CNR1KCNH2 | |
| SCHEMBL583992 | 0.84 | CNR2 (0.76) | CNR2CNR1KCNH2 | |
| SCHEMBL1609531 | 0.84 | CNR2 (0.68) | CNR2CNR1KCNH2 | |
| Hydrochloric Acid SCHEMBL1609279 | 0.83 | CNR2 (0.67) | CNR2CNR1KCNH2 | |
| SCHEMBL3756608 | 0.83 | CNR2 (0.65) | CNR2CNR1KCNH2 | |
| SCHEMBL1609270 | 0.82 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL5132524 | 0.81 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL5132528 | 0.81 | CNR2 (0.65) | CNR2CNR1KCNH2 | |
| SCHEMBL584109 | 0.80 | CNR2 (1.00) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20100022610-A1 | New Crystalline Forms | BOHLIN MARTIN | 2010-01-28 | — | — | US | disclosed |
| US-20100022610-A1 | New Crystalline Forms | BOHLIN MARTIN | 2010-01-28 | — | — | US | disclosed |
| US-20100022610-A1 | New Crystalline Forms | BOHLIN MARTIN | 2010-01-28 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007108754-A1 | CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL] -LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225346-A1 | Crystalline Forms | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225346-A1 | Crystalline Forms | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225346-A1 | Crystalline Forms | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1797077-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| WO-2006033631-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CNR2 83/4885CNR1 54/4885KCNH2 397/4885 |
| US-20110086853-A1 | Therapeutic Compounds | OPRL1, F12, F3 | CNR2 187/4885CNR1 35/4885KCNH2 795/4885 |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | OPRM1, OPRL1, OPRK1 | CNR2 13/4885CNR1 5/4885KCNH2 274/4885 |
| US-20100022610-A1 | New Crystalline Forms | ME1, TST, FH | CNR2 4419/4885CNR1 4422/4885KCNH2 2472/4885 |
| US-20070225346-A1 | Crystalline Forms | TST, ME1, FH | CNR2 4386/4885CNR1 4362/4885KCNH2 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.